

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/522119
DTOT Rec'd PCT 25 JAN 2005

Application No.: Based on PCT/JP03/09386
Filed: Intl. Filing 24 JULY 2003
1st Inventor: Yoshihisa Inoue
For: Furoisoquinoline Derivative and Use Thereof
Atty. Dkt. No. 3073 USOP

Art Unit: tba
Examiner: tba
Allowed:
Batch:
Paper No.:

Information Disclosure Statement

MAIL STOP PCT
P.O. Box 1450
Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Form PTO/SB/08A and 08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.


Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Dated: 1/5/05

(847) 383-3372
(847) 383-3391

Respectfully submitted



Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA

BEST AVAILABLE COPY

BEST AVAILABLE COPY

DT01 Rec'd PCT/PT 25 JAN 2005

PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

10/522119

Application Number	Based on PCT/JP03/09386
Filing Date	Intl. Filing 24 JULY 2003
First Named Inventor	Yoshihisa Inoue
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3073 USOP

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A4	E. PINTO, et al., "An Improved synthesis of 1(2H)-isoquinolinones: Synthesis and Biological Activity of Novel 2H-pyrando[2,3-h]isoquinolin-1,10-diones and 1(2H)-furo[2,3-h]isoquinolines", Indian Journal of Chemistry, (1992), pp. 578-582, Vol. 31B	
	A5	E. PINTO, et al., "Synthesis and Biological Activity of Novel 1 (2H)-furo[2,3-h]isoquinolinone, (2H)-pyrano[2,3-h]isoquinoline-1,8-dione", Indian Journal of Chemistry, (1994), pp. 552-555, Vol. 33B	
	A6	S.B. CHRISTENSEN, et al., "1,4-Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosphodiesterase 4 for the Treatment of Asthma", J. Med. Chem., (1998), pp. 821-835, Vol. 41	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.